An update on malignant melanoma vaccine research: Insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines

American Journal of Clinical Dermatology

Volumn 8, Issue 3, 2007, Pages 123-141

  Ralph, Stephen John ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; CANVAXIN; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; JANUS KINASE; MELANOMA VACCINE; ONCOVAX; STAT PROTEIN; TICILIMUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; BONE MARROW CELL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHROMOSOME 9P; CHROMOSOME DELETION; CLINICAL TRIAL; CYTOLOGY; DISEASE FREE SURVIVAL; DNA DAMAGE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; HETEROZYGOSITY LOSS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LYMPHOCYTE TRANSFER; MALIGNANT TRANSFORMATION; MELANOMA; MELANOMA CELL; MICROENVIRONMENT; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; TUMOR RESISTANCE;

BIOMEDICAL RESEARCH; CANCER VACCINES; CLINICAL TRIALS, PHASE III; DRUG DESIGN; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; INTERFERONS; JANUS KINASES; MELANOMA; MYELOID CELLS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SEQUENCE DELETION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34347210289     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708030-00001     Document Type: Review

References (206)

1. Dezfouli S, Hatzinisiriou I, Ralph SJ. Use of cytokines in cancer vaccines/immunotherapy: recent developments improve survival rates for patients with metastatic malignancy. Curr Pharm Des 2005; 11 (27): 3511-30
2. Bystryn JC, Reynolds SR. Melanoma vaccines: what we know so far. Oncology (Williston Park) 2005 Jan; 19 (1): 97-108
3. Jack A, Boyes C, Aydin N, et al. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg Oncol 2006 Jun 29; 15 (1): 13-24
4. Faries MB. Evaluation of immunotherapy in the treatment of melanoma. Surg Oncol Clin N Am 2006 Apr; 15 (2): 399-418
5. Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006 Apr 1; 12 (7 Pt 2): 2331s-6s
6. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006 Apr 1; 12 (7 Pt 2): 2337s-41s
7. Ribas A. Update on immunotherapy for melanoma. J Natl Compr Canc Netw 2006 Aug 4; (7): 687-94
8. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004 Oct 5; 101 Suppl. 2: 14639-45
9. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005 Apr 1; 23 (10): 2346-57
10. Gattinoni L, Powell Jr DJ, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006 May; 6 (5): 383-93
11. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004 Dec 15; 173 (12): 7125-30
12. Saleh F, Renno W, Klepacek I, et al. Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccine. Curr Pharm Des 2005; 11 (27): 3531-43
13. Saleh F, Renno W, Klepacek I, et al. Melanoma immunotherapy: past, present, and future. Curr Pharm Des 2005; 11 (27): 3461-73
14. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003 Jun; 52 (6): 387-95
15. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002 Dec 1; 20 (23): 4549-54
16. Fridman WH. Principles of the therapeutic use of monoclonal antibodies in oncology. C R Biol 2006 Apr; 329 (4): 255-9
17. McCarthy WH, Shaw HM, Thompson JF, et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988 Jun; 166 (6): 497-502
18. Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998 Apr; 67 (4): 228-33
19. Choudhury A, Mosolits S, Kokhaei P, et al. Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res 2006; 95: 147-202
20. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001 Jul; 7 (7): 1882-7
21. Dillman RO, Beutel L, Nayak S, et al. Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes? Cancer Biother Radiopharm 2005 Aug; 20 (4): 373-8
22. Restifo NP, Rosenberg SA. Use of standard criteria for assessment of cancer vaccines. Lancet Oncol 2005 Jan; 6 (1): 3-4
23. He YF, Wang XH, Zhang GM, et al. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 2005 Sep; 54 (9): 891-7
24. Mann A, Breuhahn K, Schirmacher P, et al. Up- and down-regulation of granulocyte/macrophage-colony stimulating factor activity in murine skin increase susceptibility to skin carcinogenesis by independent mechanisms. Cancer Res 2001 Mar 1; 61 (5): 2311-9
25. Eves P, Haycock J, Layton C, et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer 2003 Nov 17; 89 (10): 2004-15
26. Eves PC, MacNeil S, Haycock JW. Alpha-melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006 Feb; 27 (2): 444-52
27. Ralph SJ, Low P, Dong L, et al. Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents. Recent Patents Anti-Cancer Drug Discov 2006 Nov; 1 (3): 327-46
28. Miller AJ, Mihm Jr MC. Melanoma. N Engl J Med 2006 Jul 6; 355 (1): 51-65
29. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005 Nov 17; 353 (20): 2135-47
30. Wellbrock C, Weisser C, Hassel JC, et al. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 2005 Sep 20; 15 (18): 1629-39
31. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002 Jun 27; 417 (6892): 949-54
32. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002 Dec 1; 62 (23): 6997-7000
33. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002 Jul; 2 (1): 5-7
34. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003 Feb 15; 63 (4): 756-9
35. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003 Jul 15; 63 (14): 3883-5
36. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006 Apr; 16 (2): 97-103
37. Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003 Dec 15; 9 (17): 6483-8
38. Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006 Aug; 16 (4): 267-73
39. Bauer J, Curtin JA, Pinkel D, et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007 Jan; 127 (1): 179-82
40. Lee JY, Dong SM, Shin MS, et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun 1997 Aug 28; 237 (3): 667-72
41. Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998 Feb; 29 (2): 127-30
42. Soto JL, Cabrera CM, Serrano S, et al. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 2005 Apr 8; 5 (1): 36
43. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001 Jan 11; 409 (6817): 207-11
44. Soengas MS, Gerald WL, Cordon-Cardo C, et al. Apaf-1 expression in malignant melanoma. Cell Death Differ 2006 Feb; 13 (2): 352-3
45. Dai DL, Martinka M, Bush JA, et al. Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 2004 Sep 13; 91 (6): 1089-95
46. Baldi A, Santini D, Russo P, et al. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 2004 Feb; 13 (2): 93-7
47. Mustika R, Budiyanto A, Nishigori C, et al. Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res 2005 Feb; 18 (1): 59-62
48. Niedojadlo K, Labedzka K, Lada E, et al. Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. Pigment Cell Res 2006 Feb; 19 (1): 43-50
49. Anichini A, Mortarini R, Sensi M, et al. APAF-1 signaling in human melanoma. Cancer Lett 2006 Jul 18; 238 (2): 168-79
50. Niu G, Bowman T, Huang M, et al. Roles of activated Src and STAT3 signaling in melanoma tumor cell growth. Oncogene 2002 Oct 10; 21 (46): 7001-10
51. Burdelya L, Kujawski M, Niu G, et al. STAT3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005 Apr 1; 174 (7): 3925-31
52. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005 Jun; 24 (2): 315-27
53. Mirmohammadsadegh A, Hassan M, Bardenheuer W, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006 Oct; 126 (10): 2272-80
54. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997 Nov 7; 272 (45): 28779-85
55. Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000 Mar 1; 85 (5): 720-5
56. Kovarik J, Boudny V, Kocak I, et al. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 2003 Sep; 12 (3): 335-40
57. Boudny V, Kocak I, Lauerova L, et al. Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients. Folia Biol (Praha) 2003; 49 (4): 142-6
58. Boudny V, Dusek L, Adamkova L, et al. Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients. Neoplasma 2005; 52 (4): 330-7
59. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994 Sep; 8 (1): 23-6
60. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994 Apr 15; 264 (5157): 436-40
61. Weaver-Feldhaus J, Gruis NA, Neuhausen S, et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci U S A 1994 Aug 2; 91 (16): 7563-7
62. Holland EA, Beaton SC, Edwards BG, et al. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 1994; 9: 1361-5
63. Flores JF, Walker GJ, Glendening JM, et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996 Nov 1; 56 (21): 5023-32
64. Healy E, Sikkink S, Rees JL. Infrequent mutation of p16INK4 in sporadic melanoma. J Invest Dermatol 1996 Sep; 107 (3): 318-21
65. Wagner SN, Wagner C, Briedigkeit L, et al. Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol 1998 Jan; 138 (1): 13-21
66. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998 Feb; 16 (2): 670-82
67. Fujimoto A, Morita R, Hatta N, et al. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 1999 Apr 15; 18 (15): 2527-32
68. Kumar R, Smeds J, Lundh Rozell B, et al. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 1999 Apr; 9 (2): 138-47
69. Imieri G, Cossu A, Ascierto PA, et al. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases: the Melanoma Cooperative Group. Br J Cancer 2000 Dec; 83 (12): 1707-14
70. Hussein MR, Sun M, Tuthill RJ, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 2001 Aug; 28 (7): 343-50
71. Rubben A, Bogdan I, Grussendorf-Conen EI, et al. Loss of heterozygosity and microsatellite instability in acquired melanocytic nevi: towards a molecular definition of the dysplastic nevus. Recent Results Cancer Res 2002; 160: 100-10
72. Casorzo L, Luzzi C, Nardacchione A, et al. Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. Melanoma Res 2005 Jun; 15 (3): 155-60
73. Hussein MR, Sun M, Roggero E, et al. Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 2002 May; 34 (1): 35-44
74. Matsuoka M, Tani K, Asano S. Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages. Oncogene 1998 Apr 23; 16 (16): 2075-86
75. Sangfelt O, Erickson S, Castro J, et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999 May 6; 18 (18): 2798-810
76. Parmar S, Platanias LC. Interferons. Cancer Treat Res 2005; 126: 45-68
77. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005 May; 5 (5): 375-86
78. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006 Apr 1; 106 (7): 1431-42
79. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006 Feb 16; 354 (7): 709-18
80. Platz A, Hansson J, Mansson-Brahme E, et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997 May 21; 89 (10): 697-702
81. Della Torre G, Pasini B, Frigerio S, et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 2001 Sep 14; 85 (6): 836-44
82. Mistry SH, Taylor C, Randerson-Moor JA, et al. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 2005 Nov; 44 (3): 292-300
83. Olopade OI, Bohlander SK, Pomykala H, et al. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 1992 Oct; 14 (2): 437-43
84. Diaz MO, Pomykala HM, Bohlander SK, et al. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 1994 Aug; 22 (3): 540-52
85. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999; 50: 401-23
86. Hanson C, Kopf I, Weijdegard B, et al. Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines. Melanoma Res 1999 Oct; 9 (5): 451-6
87. Colamonici OR, Domanski P, Platanias LC, et al. Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha/beta genes in acute leukemia cell lines suggests selection against the IFN system. Blood 1992 Aug 1; 80 (3): 744-9
88. Salmon SE, Durie BG, Young L, et al. Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1983; 1 (3): 217-25
89. Schiller JH, Willson JK, Bittner G, et al. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. J Interferon Res 1986; 6 (6): 615-25
90. Salmon SE. Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 1984; 68 (1): 117-25
91. Meyskens Jr FL, Loescher L, Moon TE, et al. Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. J Clin Oncol 1984; 2: 1223-8
92. Mattei S, Colombo MP, Melani C, et al. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994 Mar 15; 56 (6): 853-7
93. Linge C, Gewert D, Rossmann C, et al. Interferon system defects in human malignant melanoma. Cancer Res 1995 Sep 15; 55 (18): 4099-104
94. Price KL, Herlyn M, Dent CL, et al. The prevalence of interferon-alpha transcrip tion defects in malignant melanoma. Melanoma Res 2005 Apr; 15 (2): 91-8
95. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004 Aug 1; 64 (15): 5270-82
96. Levy DE, Marie I, Smith E, et al. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res 2002 Jan; 22 (1): 87-93
97. Lazar-Molnar E, Hegyesi H, Toth S, et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000 Jun; 12 (6): 547-54
98. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993 Mar; 120 (5): 1281-8
99. Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005 Jun; 2 (6): 315-24
100. Niu G, Wright KL, Ma Y, et al. Role of STAT3 in regulating p53 expression and function. Mol Cell Biol 2005 Sep; 25 (17): 7432-40
101. Bedogni B, Welford SM, Cassarino DS, et al. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 2005 Dec; 8 (6): 443-54
102. Frede S, Stockmann C, Freitag P, et al. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J 2006 Jun 15; 396 (3): 517-27
103. Gray MJ, Zhang J, Ellis LM, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005 Apr 28; 24 (19): 3110-20
104. Xu Q, Briggs J, Park S, et al. Targeting STAT3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005 Aug 25; 24 (36): 5552-60
105. Socolovsky M, Fallon AEJ, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in STAT5a -/- 5b -/- mice: a direct role for STAT5 in Bcl-X(L) induction. Cell 1999; 98: 181-91
106. Johns TG, Mackay IR, Callister KA, et al. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 1992; 84 (15): 1185-90
107. Wines BD, Choe CC, Hatzinisiriou I, et al. A colourimetric dye assay to detect antiviral activity of interferons: sensitivity for measuring cellular responsiveness to interferons. Biochem Mol Biol Int 1993; 31 (6): 1111-20
108. Ralph SJ, Wines BD, Payne MJ, et al. Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation: induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitors. J Immunol 1995; 154: 2248-56
109. Wong LH, Hatzinisiriou I, Devenish RJ, et al. IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J Immunol 1998; 160: 5475-84
110. Chawla-Sarkar M, Leaman DW, Jacobs BS, et al. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (STAT1). J Interferon Cytokine Res 2002; 22: 603-13
111. Wong LH, Sim H, Chatterjee-Kishore M, et al. Isolation and characterization of a human STAT1 gene regulatory element: inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. J Biol Chem 2002 May 31; 277 (22): 19408-17
112. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 1996; 16: 275-81
113. Herrero C, Hu X, Li WP, et al. Reprogramming of IL-10 activity and signaling by IFN-gamma. J Immunol 2003 Nov 15; 171 (10): 5034-41
114. Lopez M, Aguilera R, Perez C, et al. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. Immunobiology 2006; 211 (1-2): 127-36
115. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. Nat Med 2004 Jan; 10 (1): 48-54
116. McCarter M, Clarke J, Richter D, et al. Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 2005 Aug; 138 (2): 321-8
117. Doherty GM, Tsung K, McCluskey B, et al. Endogenous interferon-gamma acts directly on tumor cells in vivo to suppress growth. J Surg Res 1996; 64: 68-74
118. Kageshita T, Hirai S, Ono T, et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 745-54
119. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004 Oct; 53 (10): 844-54
120. Seliger B. Strategies of tumor immune evasion. BioDrugs 2005; 19 (6): 347-54
121. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90: 1-50
122. Aisner DL, Maker A, Rosenberg SA, et al. Loss of S100 antigenicity in metastatic melanoma. Hum Pathol 2005 Sep; 36 (9): 1016-9
123. Saleh FH, Crotty KA, Hersey P, et al. Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens. J Pathol 2003; 200: 383-95
124. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunol 2002; 3: 999-1005
125. Levitsky HI. When magic bullets miss their mark [editorial]. Blood 2001; 97: 833
126. Dezfouli S, Hatzinisiriou I, Ralph SJ. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells. Immunol Cell Biol 2003 Dec; 81 (6): 459-71
127. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999 Mar 2; 96 (5): 2233-8
128. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001 Jun 28; 411 (6841): 1058-64
129. Ellem KA, O'Rourke MG, Johnson GR, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10-20
130. Waanders GA, Rimoldi D, Lienard D, et al. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin Cancer Res 1997; 3: 685-96
131. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208
132. Klein J, Sato A. The HLA system: first of two parts. N Engl J Med 2000; 343: 702-9
133. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273
134. Saleh FH, Crotty KA, Hersey P, et al. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 2001; 94: 551-7
135. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14: 178-82
136. Seiter S, Monsurro V, Nielsen MB, et al. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother 2002; 25: 252-63
137. Svane IM, Boesen M, Engel AM. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors: lessons from normal and immunodeficient mice. Med Oncol 1999; 16: 223-38
138. Marshall JA, Forster TH, Purdie DM, et al. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol Cell Biol 2006 Jun; 84 (3): 295-302
139. Zhou G, Lu Z, McCadden JD, et al. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004 Dec 20; 200 (12): 1581-92
140. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999 Jun; 5 (6): 677-85
141. Pure E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol 2005 Dec; 6 (12): 1207-10
142. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006 Apr 1; 12 (7 Pt 2): 2326s-30s
143. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005 Sep 1; 437 (7055): 141-6
144. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005 Nov 1; 175 (9): 6169-76
145. Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005 May 1; 174 (9): 5215-23
146. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005 Jan 17; 201 (2): 241-8
147. Appay V, Jandus C, Voelter V, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006 Aug 1; 177 (3): 1670-8
148. King IL, Segal BM. Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells. J Immunol 2005 Jul 15; 175 (2): 641-5
149. Heinzerling L, Burg G, Dummer R, et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005 Jan; 16 (1): 35-48
150. Wang RF. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res 2006 May 15; 66 (10): 4987-90
151. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004 Mar 8; 90 (5): 955-61
152. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004 Mar 1; 103 (5): 1787-90
153. Marriott JB, Clarke IA, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002 Oct; 130 (1): 75-84
154. Bedogni B, Powell MB. Skin hypoxia: a promoting environmental factor in melanomagenesis. Cell Cycle 2006 Jun; 5 (12): 1258-61
155. Michaylira CZ, Nakagawa H. Hypoxic microenvironment as a cradle for melanoma development and progression. Cancer Biol Ther 2006 May; 5 (5): 476-9
156. Ivanov SV, Salnikow K, Ivanova AV, et al. Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene 2007 Feb 8; 26 (6): 802-12
157. Joung YH, Park JH, Park T, et al. Hypoxia activates signal transducers and activators of transcription 5 (STAT5) and increases its binding activity to the GAS element in mammary epithelial cells. Exp Mol Med 2003 Oct 31; 35 (5): 350-7
158. Lee MY, Joung YH, Lim EJ, et al. Phosphorylation and activation of STAT proteins by hypoxia in breast cancer cells. Breast 2006 Apr; 15 (2): 187-95
159. Lauerova L, Dusek L, Simickova M, et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002; 49 (3): 159-66
160. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003 Dec; 13 (6): 401-7
161. Hussein MR. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol 2006 Jun; 87 (3): 163-76
162. Nesbit M, Schaider H, Miller TH, et al. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001 Jun 1; 166 (11): 6483-90
163. Miracco C, De Nisi MC, Arcuri F, et al. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Int J Oncol 2006 Feb; 28 (2): 345-52
164. Varney ML, Johansson SL, Singh RK. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 2005 Oct; 15 (5): 417-25
165. Kim MS, Day CJ, Selinger CI, et al. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. J Biol Chem 2006 Jan 13; 281 (2): 1274-85
166. Serfling E, Klein-Hessling S, Palmetshofer A, et al. NFAT transcription factors in control of peripheral T cell tolerance. Eur J Immunol 2006 Nov; 36 (11): 2837-43
167. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A 2005 Apr 5; 102 (14): 5138-43
168. Rudensky AY, Gavin M, Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006 Jul 28; 126 (2): 253-6
169. Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006 Jul 28; 126 (2): 375-87
170. Varney ML, Olsen KJ, Mosley RL, et al. Paracrine regulation of vascular endothelial growth factor-a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res 2005 Nov; 25 (11): 674-83
171. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006 Jan 15; 66 (2): 1123-31
172. Sinha P, Clements VK, Miller S, et al. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005 Nov; 54 (11): 1137-42
173. Chakraborty NG, Chattopadhyay S, Mehrotra S, et al. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 2004 Aug; 65 (8): 794-802
174. Prasad SJ, Farrand KJ, Matthews SA, et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 2005 Jan 1; 174 (1): 90-8
175. Liu A, Hu P, Khawli LA, et al. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res 2005 Dec 1; 11 (23): 8492-502
176. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005 Dec; 115 (12): 3623-33
177. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006 Feb; 16 (1): 53-65
178. Gallagher PG, Bao Y, Prorock A, et al. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res 2005 May 15; 65 (10): 4134-46
179. van den Brule F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J 2004; 19 (7-9): 537-42
180. Stillman BN, Hsu DK, Pang M, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 2006 Jan 15; 176 (2): 778-89
181. Vereecken P, Zouaoui Boudjeltia K, Debray C, et al. High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol 2006 Jan; 31 (1): 105-9
182. Zubieta MR, Furman D, Barrio M, et al. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006 May; 168 (5): 1666-75
183. Camby I, Mercier ML, Lefranc F, et al. Galectin-1: a small protein with major functions. Glycobiology 2006 Nov; 16 (11): 137R-57R
184. Toscano MA, Commodaro AG, Ilarregui JM, et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol 2006 May 15; 176 (10): 6323-32
185. van der Leij J, van den Berg A, Blokzijl T, et al. Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response. J Pathol 2004 Dec; 204 (5): 511-8
186. van der Leij J, van den Berg A, Harms G, et al. Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol Immunol 2007 Jan; 44 (4): 506-13
187. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004 Mar; 5 (3): 241-51
188. Sharpe AH, Abbas AK. T-cell costimulation: biology, therapeutic potential, and challenges. N Engl J Med 2006 Sep 7; 355 (10): 973-5
189. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitu mor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005 Dec 1; 175 (11): 7746-54
190. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003 Jul 8; 100 (14): 8372-7
191. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005 Sep 1; 23 (25): 6043-53
192. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec; 12 (12): 1005-16
193. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006 Jul-Aug; 29 (4): 455-63
194. Gomez-Navarro J, Sharma A, Bozon V, et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma: proceedings of ASCO annual meeting: part I [abstract]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 8032
195. Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006 Jun 1; 106 (11): 2437-44
196. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005 Dec 10; 23 (35): 8968-77
197. Gerritsen W, Van Den Eertwegh AJ, De Gruijl T, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC): proceedings of ASCO annual meeting: part I [abstract]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 2500
198. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006 Apr 1; 12 (7 Pt 2): 2353s-8s
199. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenviron ment. J Immunother 2006 May-Jun; 29 (3): 233-40
200. Lizee G, Radvanyi LG, Overwijk WW, et al. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 2006 Apr 1; 12 (7 Pt 2): 2359s-65s
201. Lizee G, Radvanyi LG, Overwijk WW, et al. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006 Aug 15; 12 (16): 4794-803
202. Reynolds SR, Albrecht J, Shapiro RL, et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003 Apr; 9 (4): 1497-502
203. Uyl-de Groot CA, Vermorken JB, Hanna Jr MG, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005 Mar 18; 23 (17-18): 2379-87
204. Harris JE, Ryan L, Hoover Jr HC, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000 Jan; 18 (1): 148-57
205. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004 Feb 21; 363 (9409): 594-9
206. DiFronzo LA, Gupta RK, Essner R, et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002 Aug 1; 20 (15): 3242-8